Acceleron to Present at the Leerink Partners 7th Annual Global Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 31, 2018-- Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that members of the management team will present at the Leerink Partners 7^th Annual Global Healthcare Conference on February 15, 2018 at 3:30 p.m. EST in New York, NY.

A live audio webcast will be available on the Investors/Media page of the Company's website at www.acceleronpharma.com. A replay of the webcast will be available approximately two hours after the event on the Acceleron website.

About Acceleron

Acceleron is a Cambridge-based, clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. The Company's leadership in the understanding of TGF-beta biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair.

Acceleron focuses its research and development efforts in hematologic, neuromuscular, and pulmonary diseases. In hematology, the Company and its global collaboration partner, Celgene, are developing luspatercept for the treatment of chronic anemia in myelodysplastic syndromes, beta-thalassemia, and myelofibrosis. Acceleron is also advancing its neuromuscular franchise with two distinct Myostatin+ agents, ACE-083 and ACE-2494, and a pulmonary program with a Phase 2 trial of sotatercept planned in pulmonary arterial hypertension.

For more information, please visit www.acceleronpharma.com. Follow Acceleron on Social Media: @AcceleronPharma and LinkedIn.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180131005357/en/

Source: Acceleron Pharma

For Acceleron:
Investors:
Todd James, IRC, 617-649-9393
Vice President, Investor Relations and Corporate Communications
or
Candice Ellis, 617-649-9226
Manager, Investor Relations and Corporate Communications
or
Media:
BMC Communications
Brad Miles, 646-513-3125